ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > U.S. FDA staff says effectiveness data to support approval .

<< Previous

Bullboard Posts

Next >>

Comment by M101on Nov 04, 2020 12:09pm

101 Views

Post# 31835962

RE:U.S. FDA staff says effectiveness data to support approval .

So the market says it's a sure thing now, and thanks to the brilliant strategy of Gene and Elliot the only upside for PMN is that this doesn't cause a sell off.

<< Previous

Bullboard Posts

Next >>

Mid-year update: Charting GameSquare’s sharp business growth